Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing
Posted:
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.
Read the full article in the latest MedCity News blog post here.
Peter Kyle calls on employees and businesses to act now to get to grips with technology amid forecasts of job losses.
Breakthroughs such as the emergence of ChatGPT have sparked an investment boom in the technology, but also led to forecasts that…
The company will use the funds to increase the adoption of its new offering, Sage, across healthcare providers, payers and care management organizations.
Ellipsis Health, a company using AI voice agent technology, announced it has raised $45 million in a new…
Attendees
Sponsors and Exhibitors
Contact us